Biotech Values

[genisi]

BMY's anti-PD-L1 is for viral infection, not oncology.

They have tested it in oncology but activity was not as impressive as with the anti PD-1.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94713

I see an anti-PD-L1 (in virology, probably HCV) in Bristol's pipeline but cannot find anything going on with this agent in the clinic. Btw, they also tested the anti PD-1 in HCV but didn't go on since phase I, which ended in 2009.